Recommendations for research

Recommendations for research

As part of the 2019 update, the guideline committee made 2 new research recommendations (marked [2019]). Research recommendations retained from the 2013 guideline are labelled [2013].

Key recommendations for research

1 Risk stratification for contrast-induced acute kidney injury

Can risk of contrast-induced acute kidney injury be stratified by eGFR thresholds? [2019]

For a short explanation of why the committee made the research recommendation on risk stratification for contrast-induced acute kidney injury see rationale and impact.

Full details of the research recommendation are in evidence review A: preventing contrast-induced acute kidney injury.

2 Different oral fluids and oral fluid regimens

What is the relative effectiveness and cost effectiveness of different oral fluids and different oral fluid regimens, both with and without oral N-acetylcysteine, at preventing contrast-induced acute kidney injury? [2019]

For a short explanation of why the committee made the research recommendation on different oral fluids and oral fluid regimens see rationale and impact.

Full details of the research recommendation are in evidence review A: preventing contrast-induced acute kidney injury.

3 Long-term outcomes of acute kidney injury

What are the long-term outcomes of acute kidney injury in adults, children and young people? [2013]

4 Rapid referral to nephrology services for moderate to severe acute kidney injury

What is the clinical and cost effectiveness of rapid referral (within 12 hours) to nephrology services for adults with moderate to severe (stage 2 to 3) acute kidney injury not needing critical care? [2013]

5 Definition of acute kidney injury – system for staging and detection

Can a simplified definition and staging system, based on Système International (SI) units, be used to predict short- to medium-term outcomes in acute kidney injury? [2013]

6 Introducing renal replacement therapy

What is the clinical and cost effectiveness of early versus later introduction of renal replacement therapy in patients with acute kidney injury stages 2 and 3, when there is no urgent need for therapy? [2013]

7 Preventing deterioration

What is the clinical and cost effectiveness of continuing ACE inhibitor or ARB treatment, versus stopping treatment 24 hours before cardiac surgery and resuming 24 hours after, in people with chronic kidney disease and an eGFR of less than 30 ml/min/1.73m2? [2013]

  • National Institute for Health and Care Excellence (NICE)